BioSpace News Archive

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will be presenting two abstracts at the EORTC-NCI-AACR Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020.

150ppm nitric oxide was statistically significant compared to both control and 85ppm nitric oxide arms on the primary and key secondary endpoints

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that it has signed an agreement with the Israeli Ministry of Health to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin product for the treatment of coronavirus patients in Israel.

Aptose Biosciences Inc. announced dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor that potently inhibits the wildtype and mutant forms of FLT3 and BTK, and suppresses select clusters of kinases that drive oncogenic signaling pathways.

Clinical trial will evaluate the effectiveness of MediPharm Labs proprietary GMP cannabis-derived formulations and medical products and expand MediPharm Labs owned IP In the United States, 37 million or more than 1 in 7 adults, are estimated to have chronic kidney disease (CKD) and Worldwide, approximately 1 in 10 people suffer from kidney disease according to the National Kidney Foundation Patients with CKD suffer from various symptoms and have limited life expectancy, consequently, optimi

CareDx, Inc. announced that the Centers for Medicare and Medicaid Services recently issued a memo recommending continued coverage of AlloMap through local Medicare Administrative Contractors.

CareDx, Inc. announced that it will share the latest data on CareDx products for HLA laboratories at the 46th annual meeting of The American Society for Histocompatibility and Immunogenetics.

ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistance

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

First data for 18 months of treatment with intravitreal pegcetacoplan demonstrates continued slowing of GA lesion growth beyond 12 months